Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.56 |
| ▸ | ACSS2 | Q9NR19 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248717 | 0.91 | DGAT1 (0.48) | DGAT1ACSS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1249925 | 0.90 | DGAT1 (0.47) | DGAT1ACSS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1250280 | 0.86 | DGAT1 (0.61) | DGAT1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1250538 | 0.85 | ACSS2 (0.49) | DGAT1ACSS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1250558 | 0.84 | MAPT (0.46) | DGAT1ACSS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1249228 | 0.84 | RAB9A (0.48) | DGAT1ACSS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3167934 | 0.82 | PTGER4 (0.49) | ACSS2 | |
| SCHEMBL1250370 | 0.78 | DGAT1 (0.53) | DGAT1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1251403 | 0.76 | DGAT1 (0.51) | DGAT1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1250473 | 0.73 | ESR2 (0.49) | DGAT1NPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885ACSS2 128/4885NPC1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.